Connor Clark & Lunn Investment Management Ltd. Buys 98,957 Shares of Keros Therapeutics, Inc. $KROS

Key Points

• Connor Clark & Lunn Investment Management Ltd. increased its stake in Keros Therapeutics by 339.5% in Q1, owning approximately 0.32% of the shares valued at $1.31 million.
• Institutional investors own 71.56% of Keros Therapeutics, with Vanguard Group increasing its holdings by 31.1% and Federated Hermes by a staggering 882.3% in the same period.
• Recent analyst ratings reflect a mixed outlook, with price targets being cut by firms like Scotiabank and Bank of America, leading to an average target price of $30.00 and a overall rating of "Moderate Buy."

Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 339.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 128,103 shares of the company's stock after acquiring an additional 98,957 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.32% of Keros Therapeutics worth $1,305,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. MetLife Investment Management LLC boosted its stake in Keros Therapeutics by 6.0% in the 4th quarter. MetLife Investment Management LLC now owns 18,098 shares of the company's stock worth $286,000 after purchasing an additional 1,027 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Keros Therapeutics by 7.8% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,184 shares of the company's stock worth $303,000 after purchasing an additional 1,386 shares during the period. Virtus ETF Advisers LLC boosted its stake in Keros Therapeutics by 107.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after purchasing an additional 1,998 shares during the period. GAMMA Investing LLC boosted its stake in Keros Therapeutics by 7,690.3% in the 1st quarter. GAMMA Investing LLC now owns 2,415 shares of the company's stock worth $237,000 after purchasing an additional 2,384 shares during the period. Finally, FNY Investment Advisers LLC bought a new position in Keros Therapeutics in the 1st quarter worth approximately $25,000. 71.56% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

KROS has been the subject of several recent analyst reports. Wedbush restated a "neutral" rating and issued a $15.00 price target on shares of Keros Therapeutics in a research note on Friday, May 30th. Scotiabank dropped their price target on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday, May 12th. HC Wainwright dropped their price target on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Bank of America cut Keros Therapeutics from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $32.00 to $18.00 in a report on Tuesday, June 10th. Seven equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $30.00.

Keros Therapeutics Stock Performance

Shares of KROS traded up $0.94 during mid-day trading on Thursday, hitting $15.17. 1,036,402 shares of the stock were exchanged, compared to its average volume of 419,518. The company has a market cap of $616.21 million, a PE ratio of 48.94, a price-to-earnings-growth ratio of 1.75 and a beta of 1.33. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37. The firm has a 50-day moving average of $14.00 and a two-hundred day moving average of $12.95.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.38. The business had revenue of $0.02 million for the quarter, compared to analysts' expectations of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The company's revenue for the quarter was up 49002.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.25) EPS. On average, sell-side analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.